This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Does the Stock of Cigna (CI) Look Attractive Now?
by Zacks Equity Research
The acquisition of Express Scripts by Cigna (CI) presents another major growth point for the company.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Cigna Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cigna Corporation has been struggling lately, but the selling pressure may be coming to an end soon.
Top Ranked Value Stocks to Buy for January 10th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, January 10th:
Top Ranked Value Stocks to Buy for January 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, January 9th:
Why the Earnings Surprise Streak Could Continue for Cigna (CI)
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Ranked Value Stocks to Buy for January 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, January 8th:
Cigna (CI) & Units Receive Rating Actions From A.M. Best
by Zacks Equity Research
Credit rating giant A.M. Best affirms the ratings of Cigna (CI) and its subsidiaries.
Anthem or Humana: Which HMO Stock is a Better Buy for 2019?
by Zacks Equity Research
The health insurance industry is poised for growth despite some policy disturbances; here we analyze which stock Anthem or Humana would provide greater returns in 2019.
Top Ranked Value Stocks to Buy for January 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, January 4th
Cigna (CI) Stock Moves -0.85%: What You Should Know
by Zacks Equity Research
Cigna (CI) closed the most recent trading day at $185.57, moving -0.85% from the previous trading session.
Why You Should Add Radian Group (RDN) to Your Portfolio
by Zacks Equity Research
Radian Group (RDN) rides on operational excellence and promises better rewards for investors.
Why You Should Add Brown & Brown (BRO) to Your Portfolio
by Zacks Equity Research
Brown & Brown (BRO) promises better reward for investors on operational excellence.
Tenet (THC) Signs Deal to Provide Services to Cigna Members
by Zacks Equity Research
Tenet (THC) enters new agreements to provide in-network access to Cigna members
AIG's UK Unit Closes Buyout of Ellipse, Boosts Portfolio
by Zacks Equity Research
AIG's UK arm completes the pending purchase of Ellipse to strengthen its position in Life & Retirement businesses.
MGIC Investment New Business Written Growth Momentum Sustains
by Zacks Equity Research
Lower paid claims, solid new business written, better insurance in force and a firm capital position enable MGIC Investment (MTG) to emerge as a profitable pick for yield-seeking investors.
Zacks.com featured highlights include: Allison Transmission, Restoration Hardware, Cigna, Encompass Health and O???Reilly Automotive
by Zacks Equity Research
Zacks.com featured highlights include: Allison Transmission, Restoration Hardware, Cigna, Encompass Health and O???Reilly Automotive
Cigna Poised for Growth in 2019 on Express Scripts Buyout
by Zacks Equity Research
The purchase of Express Scripts by Cigna (CI) has diversified its business, which should fuel long-term growth.
5 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Marsh & McLennan's (MMC) Unit Launches China Desk in Dubai
by Zacks Equity Research
Marsh & McLennan's (MMC) subsidiary introduces China desk in Dubai to benefit from the growing commercial links amid China, the Middle East and Africa.
Why Horace Mann (HMN) Could Be Positioned for a Slump
by Zacks Equity Research
Horace Mann (HMN) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
5 Great Healthcare Stocks to Buy for 2019
by Swarup Gupta
Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.
Cigna, Express Scripts Join Forces for Better Healthcare
by Zacks Equity Research
Cigna (CI) completes merger with Express Scripts. The new entity aims to provide affordable and flexible healthcare solutions to customers.
Cigna (CI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $193.30, marking a +0.65% move from the previous day.
4 HMOs Likely to Cruise Ahead of Industry in 2019
by Sapna Bagaria
Players in the HMO industry should gain from aging population, expanding government business, technological investment and industry consolidation